CROs in disguise

Brian Orelli at The Motley Fool writes on the basics of CROs, or CROs 101 for the non-industry professional. Orelli outlines a few characteristics of CROs but what was most interesting was his claim that some CROs can be disguised and, according to Orelli, it seems (to me) that pharmaceutical companies are essentially turning into holding companies that license or purchase drug candidates, escort them through the regulatory maze, and produce and hock them once they get past the FDA. Which he claims isn't a bad business model. Check out his piece here and let us know your thoughts.